ParticipeDone hoy
Done hoy
Done hoy

Ciberseminario

APOL1-mediated kidney disease: Overview and Implications for Care

APOL1 webinar
Nephrologist and subject matter expert, Mona Doshi, M.D., presents information about APOL1.

Learn more about APOL1-Mediated Kidney Disease (AMKD)

APOL1 as a potential genetic marker for kidney disease remains a topic new to many healthcare professionals.


It is estimated that 45% of people with African ancestry in the US carry at least one high-risk APOL1 genetic variant and 13% carry two variants, which could have certain impacts on the health of a segment of your patient population.


In this webinar, nephrologist and subject matter expert, Mona Doshi, MD, presents information that will:

  1. Raise awareness of APOL1-mediated kidney disease among healthcare professionals
  2. Educate healthcare professionals about the role of these variants in kidney genetics and their potential impact in populations of African or Hispanic/Latino descent
  3. Highlight the need for increased genetic testing and its availability for those at risk, especially in relation to minority patients

     

Moderator: Silas Norman, M.D.

Speaker: Mona Doshi, MD

Learn more about APOL1-Mediated Kidney Disease (AMKD)

This webinar is hosted by the American Kidney Fund, with generous support from

APOL1 webinar summary guide

Download an APOL1 webinar summary guide for healthcare professionals.

Download

Speaker

Mona Doshi, M.D.

Mona Doshi, M.D.

Dr. Doshi is the Co-Medical Director of Kidney-Pancreas Transplant Program and Professor of Medicine at the University of Michigan. Her research interests include improving living kidney donor selection and advancing our understanding of ischemia reperfusion injury around time of organ procurement and transplant. She serves on several multi-center NIH sponsored research projects. She also serves as a principal investigator for the NIH-funded multi-center APOLLO study to determine if the APOL1 genotype in Black deceased donors affects allograft outcomes. The findings of this study will allow the elimination of the use of race from the deceased donor kidney quality calculator (routinely used in transplantation) and instead use the results of APOL1 genetic testing. She is nationally known for her expertise in issues around living donation and serves on several national committees.